Valuation: Novacyt

Market Cap 29.06M 33.2M 26.78M 24.82M 47.12M 3.15B 47.88M 321M 125M 1.56B 125M 122M 5.38B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 31.01M 35.44M 28.58M 26.49M 50.29M 3.36B 51.1M 343M 133M 1.66B 133M 130M 5.74B EV / Sales 2026 *
1.02x
EV / Sales 2027 * 0.97x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+0.25%
1 week+1.65%
Current month+1.65%
1 month-12.83%
3 months+9.26%
6 months-1.84%
Current year+2.56%
1 week 0.39
Extreme 0.3905
0.41
1 month 0.38
Extreme 0.3765
0.52
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap.
03-29Buy

Chief Executive Officer

56,438 0.0799%
03-29Buy

Chairman

15,228 0.0216%
03-29Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%+1.65%-16.46%-16.25% 33.2M
+3.19%+9.09%-35.19%-35.98% 626M
-3.12%-23.80%+107.34% - 390M
+1.38%-4.41%-32.18%+32.19% 127M
-7.37%-9.40%+17.48%+84.08% 111M
Average -1.13%-2.61%+8.20%+16.01% 257.35M
Weighted average by Cap. +0.11%-0.50%+13.32%-10.71%

Financials

2026 *2027 *
Net sales 30.52M 34.88M 28.13M 26.07M 49.5M 3.31B 50.3M 337M 131M 1.63B 131M 128M 5.65B 34.86M 39.84M 32.13M 29.78M 56.53M 3.78B 57.44M 385M 150M 1.87B 150M 146M 6.45B
Net income - -
Net Debt 1.96M 2.24M 1.8M 1.67M 3.17M 212M 3.22M 21.62M 8.41M 105M 8.39M 8.21M 362M 4.84M 5.53M 4.46M 4.14M 7.85M 525M 7.98M 53.51M 20.81M 259M 20.77M 20.32M 896M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-07-07 €0.4010 +0.25% 174,422
26-07-06 €0.4000 -2.08% 78,301
26-07-03 €0.4085 +2.00% 80,162
26-07-02 €0.4005 -1.48% 97,800
26-07-01 €0.4065 +3.04% 252,090

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock